# Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Canonical URL: https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update
Ticker: RLMD
Company: Relmada
Source: Relmada
Published: 2026-05-12 20:05 EST
Original Source URL: https://www.relmada.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-05-28 11:00 EST — [Relmada Therapeutics to Present at the Jefferies Global Healthcare Conference](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-at-the-jefferies-global-healthcare-conference) — Source: Relmada
- 2026-05-12 20:05 EST — [Relmada Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Relmada
- 2026-05-06 11:00 EST — [Relmada Therapeutics to Report First Quarter 2026 Financial Results on Tuesday, May 12, 2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-report-first-quarter-2026-financial-results-on-tuesday-may-12-2026) — Source: Relmada
- 2026-05-05 11:00 EST — [Relmada Therapeutics to Present NDV-01 Abstracts at AUA2026](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-to-present-ndv-01-abstracts-at-aua2026) — Source: Relmada
- 2026-03-19 20:01 EST — [Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-reports-fourth-quarter-and-full-year-2025-results-and-provides-business-update) — Source: Relmada
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)